Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population

Pharmacogenetics

Volumn 7, Issue 4, 1997, Pages 327-331

  Aynacioglu, A Sükrü ^a,b   Cascorbi, Ingolf ^a   Mrozikiewicz, Przemyslaw M ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Arylamine N acetyltransferase; Genotype; Molecular epidemiology; Pharmacogenetics; Turkey

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ACETYLATION; ACETYLATOR PHENOTYPE; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC LINKAGE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; PHARMACOGENETICS; POINT MUTATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

EID: 0030789075     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199708000-00008     Document Type: Article

References (24)

1. Agúndez JAG, Olivera M, Martinez C, Ladero JM, Benitez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996: 6. 423-428.
2. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acelyltransferase (NAT2) reveals a new slow-acetylator allele commun in African-Americans. Carcinogenesis 1993: 14. 1689-1692.
3. Bozkurt A, Basci NE, Kalan S, Tuncer M, Kayaalp SO. N-acetylation phenotyping with sulphadimidine in a Turkish population. Eur J Clin Pharmacol 1990: 38. 53-56.
4. Brockmöller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994: 27. 216-248.
5. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acelyltransferase 2. glutathione N-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996: 56. 3915-3925.
6. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995: 57. 581-592.
7. Cascorbi I, Brockmöller J, Bauer S, Reum T, Roots I. NAT2*12A (803A→G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics 1996a: 6, 257-259.
8. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as susceptibility factor for lung cancer. Cancer Res 1996b: 56. 3961-3966.
9. Deloménie C, Sica L, Grant DM, Krishnamurthy R, Dupret JM. Genotyping of the polymorphic N-acelyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996: 6. 177-185.
10. Duru S. Modern tüberküloz tedavisinde bireylerin asetilasyon hizlarinin saptanmasinin önemi. Mikrobiyol Bul 1979: 13. 53-61.
11. El-Yazigi A, Chaleby K, Martin CR. Acetylator phenotypes of Saudi Arabians by a simplified caffeine metabolites test. J Clin Pharmacol 1989: 29. 246-250.
12. Evans DAP. N-acetyltransferase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. New York: Pergamon, 1992: 95-178.
13. Grant DM, Blum M, Demierre A, Meyer UA. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acid Res 1989: 17. 3978.
14. Irshaid Y, al-Hadidi H, Abuirjeie M, Latif A, Sartawi O, Ravashdeh N. Acetylator phenotypes of Jordanian diabetics. Eur J Clin Pharmacol 1992: 45. 621-623.
15. Karakaya AE, Cok I, Sardas S, Gogus O, Sardas OS. N-acetyltransferase phonotype of patients with bladder cancer. Hum Toxicol 1986: 5. 333-335.
16. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians. blacks, Hispanics and whites: application to metabolic epidemiology. Am J Hum Genet 1993: 52. 827-834
17. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator or mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994: 4. 125-134.
18. Martínez C, Agúdez JAG, Olivera M, Martin R, Ladero JM, Benitez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995: 5. 207-214.
19. Mashimo M, Suzuki T, Abe M, Degushi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992: 90. 139-143.
20. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 1996: 59. 376-382.
21. Newton CR, Graham A, Heptinstall LE, Powell SJ, Smith JC, Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989: 17. 2503-2516.
22. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995: 4. 231-236.
23. Rothman N, Hayes RB, Bi W, Caporaso N, Broly F, Woosley RL, Yin S, Feng P, You X, Meyer UA. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993: 3. 250-255.
24. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995: 5. 1-17.